Solventum Corp (SOLV)
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
- Symbol
- SOLV
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Market cap
- $15.19B
- 52 week range
- 62.38 - 94.16
Valuation
- Share price
- $88.37 (close of 2026-09-23)
- P/E (TTM)
- 10.85x
- Price to book
- 3.16x
- Price to free cash flow
- -128.74x
- Enterprise value
- $20.07B
- Book value per share
- $28.22
Price performance
| Period | Change |
|---|
| 1 day | -0.53% |
| 5 days | -1.88% |
| 1 month | -1.34% |
| 3 months | +19.44% |
| 6 months | +34.53% |
| Year to date | +11.52% |
| 1 year | +20.41% |
| All time | +10.45% |
Profitability and growth
- Return on equity
- 30.82%
- Return on invested capital
- 21.99%
- Return on assets
- 10.89%
- Return on capital employed
- 19.55%
- Gross margin
- 53.47%
- Net margin
- 18.69%
- EBITDA margin
- 32.07%
- Revenue growth
- 0.86%
- Net income growth
- 224.84%
- Free cash flow growth
- -101.24%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -0.78%
- Current ratio
- 1.02x
- Net debt to EBITDA
- 1.98x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $8.32B
- Cost of revenue
- $2.33B
- Gross profit
- $4.45B
- EBITDA
- $2.67B
- Net income
- $1.56B
- Earnings per share
- $8.94
- Research and development
- $739.00M
- Shares outstanding
- 174.10M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $8.32B | $4.45B | $1.56B | $8.94 |
| 2024-12-31 | $8.25B | $4.59B | $479.00M | $2.77 |
| 2023-12-31 | $8.20B | $4.69B | $1.35B | $7.79 |
| 2022-12-31 | $8.13B | $4.70B | $1.34B | $7.78 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 53.47% | 18.69% | 30.82% | 21.99% |
| 2024-12-31 | 55.65% | 5.80% | 16.19% | 8.91% |
| 2023-12-31 | 57.25% | 16.42% | 11.54% | 6.93% |
| 2022-12-31 | 57.75% | 16.52% | 11.44% | 11.51% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $878.00M | $5.04B |
| 2024-12-31 | $762.00M | $7.81B |
| 2023-12-31 | $194.00M | - |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-10.00M | $161.00M |
| 2024-12-31 | $805.00M | $112.00M |
| 2023-12-31 | $1.63B | $39.00M |
| 2022-12-31 | $1.43B | $37.00M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-05
- Consensus EPS estimate
- $1.35
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-05 | Jun/2026 | $1.91 |
| 2026-05-05 | - | - |
| 2026-02-26 | - | - |
| 2025-11-06 | - | - |
| 2025-08-07 | - | - |
| 2025-05-08 | - | - |
| 2025-02-27 | - | - |
| 2024-11-07 | - | - |
Filings and sources
- Company website
- solventum.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Intuitive Surgical Inc (ISRG) · Becton Dickinson & Co (BDX) · ResMed Inc (RMD) · West Pharmaceutical Services Inc (WST) · Baxter International Inc (BAX) · Align Technology Inc (ALGN) · Cooper Companies, Inc. (COO) · Vertex Pharmaceuticals Inc (VRTX)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades